Ligresti Alessia

Ligresti Alessia

    • Researchers
  • 27 Marzo 2017
  • 1194


Profile: Ricercatore

Office location: Napoli

E-mail address: Questo indirizzo email è protetto dagli spambots. E' necessario abilitare JavaScript per vederlo.

Work phone #: +39(0)818675093

Lab phone #: +39(0)818675191-5193

Biography: From June 2014 Habilitated as Associate Professor in Biochemistry and Clinical Biochemistry from MIUR (Ministry of Education, University and Research). From March 2012 Scientific Consultant for Allergan Inc. (Irvine, California). From January 2010 Research Associate Professor at Institute of Biomulecular Chemistry, CNR. From January 2008 Research Investigator at Institute of Biomulecular Chemistry, CNR. From January to October 2005 Visiting Researcher at Department of Biological Science, Allergan Inc., Irvine, Californa USA. From January 2005 Preclinical Research Collaborator for GW Pharmaceutical (project code GWCRI1173). December 2005 PhD Degree in Pharmaceutical Science, University of Naples “Federico II”, Facoltà di Farmacia. March 2001 MS Degree in Chemical and Pharmaceutical Technology, University of Naples “Federico II”, Facoltà di Farmacia.



  1. Studies on the role of Cannabinoids and Endocannabinoid System on cancer disease.
  2. Design, synthesis and characterization of biodegradable nano-particles for targeted and controlled release of bioactive molecules in animal and cellular models of highly disabling diseases.
  3. Use of ligand modified nanoparticles for the study of cellular membrane trafficking of lipid bioregulators and bioactive amides of fatty acids
  4. Biosynthesis, bioactivity and inactivation of prostamides in the CNS.
  5. Studies on structure activity relationship (SAR) for selective inhibitors of Endocannabinoid-related targets (i.e. EMT, CBR, TRP, metabolic enzymes)
  6. Studies on the role of Endogenous Cannabinoids and Brain/Immune Function
  7. Role of Endocannabinoid System in Obesity and Metabolic Syndrome

Major publications

  1. Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach. Cerasuolo M, Paris D, Iannotti FA, Melck D, Verde R, Mazzarella E, Motta A, Ligresti A. Cancer Res. 2015 Aug 1;75(15):2975-86.
  2. Prostamide F(2) α receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition. Ligresti A, Martos J, Wang J, Guida F, Allarà M, Palmieri V, Luongo L, Woodward D, Di Marzo V. Br J Pharmacol. 2014 Mar;171(6):1408-19. doi: 10.1111/bph.12410.
  3. De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013 Jan;168(1):79-102. doi:10.1111/j.1476-5381.2012.02027.x.
  4. Ligresti A, Villano R, Allarà M, Ujváry I, Di Marzo V. Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB₁ receptor ligand. Pharmacol Res. 2012 Aug;66(2):163-9. doi: 10.1016/j.phrs.2012.04.003.
  5. Ligresti A, De Petrocellis L, Hernán Pérez de la Ossa D, Aberturas R, Cristino L, Moriello AS, Finizio A, Gil ME, Torres AI, Molpeceres J, Di Marzo V. Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter. PLoS One. 2010 Apr 22;5(4):e10239. doi:10.1371/journal.pone.0010239.
  6. Ligresti A, Petrosino S, Di Marzo V. From endocannabinoid profiling to 'endocannabinoid therapeutics'. Curr Opin Chem Biol. 2009 Jun;13(3):321-31. doi: 10.1016/j.cbpa.2009.04.615.
  7. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87.
  8. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A, Visintin C, Wiley JL, Baker D, Martin BR, Razdan RK, Di Marzo V. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol. 2006 Jan;147(1):83-91.
  9. Ligresti A, Morera E, Van Der Stelt M, Monory K, Lutz B, Ortar G, Di Marzo V. Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J. 2004 May 15;380(Pt 1):265-72.
  10. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003 Sep;125(3):677-87.


Endocannabinoid System, Cancer Research, Pharmacology, Biochemistry, Nanotechnology